

2024



PROGRAM

8e édition

SYMPOSIUM DE MONTRÉAL

EN CANCER DU SEIN

Session spéciale: Tumeurs neuro-endocrines





November 21

<p>7h55 - 8h00</p>	<p>Welcome Address Dr. Rami Younan Dr. Erica Patocskai CHUM (University of Montreal Hospital Center)</p>
<p>8h00 - 8h20</p>	<p>Breast Imaging: Post-treatment Follow-up Dr. Mona EL Khoury CHUM Learning Objectives:</p> <ul style="list-style-type: none">• Examine the benefits of different breast imaging modalities.• Summarize indications for the various imaging modalities.• Describe algorithms to determine the optimal imaging approach for specific clinical scenarios.
<p>8h20 - 8h50</p>	<p>Axillary Surgery Updates Dr. Jean-François Boileau Jewish General Hospital Learning Objectives:</p> <ul style="list-style-type: none">• Identify clinical contexts where axillary surgery may be safely avoided.• Review the importance of precise axillary staging for adjuvant treatment recommendations.
<p>8h50 - 9h10</p>	<p>Breast Reconstruction Strategies Dr. Julian Diaz CHUM Learning Objectives:</p> <ul style="list-style-type: none">• Review factors considered by plastic surgeons when evaluating different breast reconstruction methods.• Explore the algorithmic approach to breast reconstruction.• Examine surgical advances in reconstruction options for patients.
<p>9:10 - 9:30</p>	<p>Updates in Radiotherapy for Breast Cancer Dr. Pierre Rousseau CHUM Learning Objectives:</p> <ul style="list-style-type: none">• Describe recent technological advances in radiotherapy for breast cancer.• Analyze the pros and cons of new radiotherapy techniques.• Integrate emerging practices into personalized treatment plans to enhance clinical outcomes.

November 21

<p>9h35 - 9h50</p>	<p>Question Period Panel: Dr. Jean-François Boileau, Dr. Pierre Rousseau, Dr. Julian Diaz, Dr. Mona El Khoury</p>
<p>9h50 - 10h15</p>	<p>Tumor Board Discussion Panel: Dr. Jean-François Boileau, Dr. Pierre Rousseau, Dr. Julian Diaz, Dr. Mona El Khoury Learning Objectives:</p> <ul style="list-style-type: none">• Analyze imaging modalities for optimal post-treatment breast cancer follow-up.• Evaluate clinical contexts to avoid axillary surgery while maintaining precise staging.• Review breast reconstruction strategies and surgical advancements.• Incorporate new radiotherapy technologies into personalized treatment plans.
<p>10h15 - 10h45</p>	<p>Break and Networking</p>
<p>10h45 - 11h35</p>	<p>Maximizing Treatment Options for Early Hormone Receptor-positive, HER2-negative Breast Cancer: A Multidisciplinary Approach Dr. Stephanie L. Graff Director of Breast Oncology, Brown University Health Learning Objectives:</p> <ul style="list-style-type: none">• Assess recurrence risk in early hormone receptor-positive, HER2-negative breast cancer.• Examine the role of genomic signature testing for this patient population.• Review implications of recent studies for treatment plans.• Discuss the clinical impact of multidisciplinary care.
<p>11h35 - 11h45</p>	<p>Question Period Dr. Stephanie L. Graff</p>

November 21

11h45 - 12h10	Gynecological Side Effects of Hormone Therapy and Their Management Dr. Jeanne Bouteaud CHUM Learning Objectives: <ul style="list-style-type: none">• Describe common post-breast cancer menopause-related issues.• Identify treatment options for frequent menopausal symptoms.• Analyze data on hormone therapy in post-breast cancer patients.
12h10 - 12h20	Question Period Dr. Jeanne Bouteaud
12h20 - 12h45	Tumor Board Discussion Panel: Dr. Stephanie L. Graff, Dr. Jeanne Bouteaud, and Dr. Rami Younan Learning Objectives: <ul style="list-style-type: none">• Explore recurrence risk factors in early hormone receptor-positive, HER2-negative breast cancer.• Address menopause-related challenges in breast cancer survivors and examine evidence-based symptom management.• Strengthen multidisciplinary collaboration in patient treatment plan
12h45 - 13h50	Lunch and Networking
13h50 - 14h15	Neuroendocrine Tumors Update Dr. Frédéric Mercier CHUM Learning Objectives: <ul style="list-style-type: none">• Recognize clinical and diagnostic features of neuroendocrine tumors.• Assess novel therapeutic approaches for neuroendocrine tumor treatment.• Apply recent knowledge to improve outcomes for neuroendocrine tumor patients.

November 21

14h15 -15h00	Systemic Treatment for Neuroendocrine Tumors: Where Are We Now? A Case Study Dr. Catherine Lombard-Bohas Edouard Herriot Hospital Learning Objectives: <ul style="list-style-type: none">• Review current systemic treatments for neuroendocrine tumors through a clinical case.• Compare therapeutic options based on tumor stage and type.• Propose strategies for personalized management of neuroendocrine tumors.
15h00 - 15h15	Question Period Panel: Dr. Frédéric Mercier and Dr. Catherine Lombard-Bohas
15h15 - 15h40	Interesting Cases in Neuroendocrine Tumors Panel: Dr. Daniel Juneau, Dr. Frédéric Mercier, and Dr. Catherine Lombard-Bohas Learning Objectives: <ul style="list-style-type: none">• Discuss atypical clinical presentations of neuroendocrine tumors through case studies.• Analyze diagnostic and therapeutic challenges posed by complex neuroendocrine tumor cases.• Develop innovative management strategies based on case reviews to enhance patient care.
15h40 - 16h00	Break and Networking
16h00 - 17h00	Four Interesting Breast Cancer Cases Learning Objectives: <ul style="list-style-type: none">• Examine unusual clinical presentations of breast cancer through four detailed cases.• Evaluate specific diagnostic and therapeutic approaches for complex breast cancer cases.• Formulate personalized treatment plans based on lessons from these case studies.

November 21

<p>16h00 - 16h15</p>	<p>Breast Cancer with Lymph Node Metastasis (HR+) Dr. Ari Meguerditchian MUHC Learning Objectives:</p> <ul style="list-style-type: none">• Describe clinical and biological characteristics of HR+ breast cancer with lymph node metastases.• Evaluate therapeutic options for HR+ metastatic breast cancer based on current recommendations.• Integrate personalized treatment strategies to improve prognosis and quality of life for patients.
<p>16h15 - 16h30</p>	<p>Residual HER2+ Disease Post-Neoadjuvant Chemotherapy in BRCA+ Patients Dr. Ghislain Courmoyer Saint-Jérôme Hospital Learning Objectives:</p> <ul style="list-style-type: none">• Analyze clinical challenges in managing residual HER2+ disease after neoadjuvant chemotherapy in BRCA+ patients.• Evaluate targeted therapeutic options for BRCA+ patients with residual HER2+ disease.• Develop personalized strategies to optimize post-chemotherapy outcomes considering genetic and biological factors.
<p>16h30 - 16h45</p>	<p>Residual ER+ Disease Post-Neoadjuvant Chemotherapy Dr. Dominique Leblanc Saint-Sacrement Hospital Learning Objectives:</p> <ul style="list-style-type: none">• Recognize clinical characteristics of residual ER+ disease post-neoadjuvant chemotherapy.• Evaluate adjuvant treatment options and targeted therapies for patients with residual ER+ disease.• Integrate recent data into post-chemotherapy treatment plans to improve clinical outcomes.
<p>16h45 - 17h00</p>	<p>Indication for Axillary Dissection Post-Sentinel Lymph Node Biopsy Dr. Élise Martel CISSS de Lanaudière Learning Objectives:</p> <ul style="list-style-type: none">• Determine clinical and pathological criteria justifying axillary dissection after a positive sentinel lymph node biopsy.• Assess risks and benefits of axillary dissection compared to other therapeutic options in breast cancer management.• Apply recent guidelines to decision-making in managing lymph node metastases post-sentinel biopsy.
<p>17h00</p>	<p>Closing Remarks</p>

November 22

<p>7h55 - 8h00</p>	<p>Welcome Address Dr. Rami Younan Dr. Erica Patocskai CHUM</p>
<p>8h00 - 8h10</p>	<p>McPeak-Sirois Consortium Update Dr. Dominique Johnson McPeak-Sirois Learning Objectives:</p> <ul style="list-style-type: none">• Describe recent progress of the McPeak-Sirois Consortium in breast cancer research and clinical trials.• Analyze the impact of new collaborations and ongoing research projects within the consortium on breast cancer care.• Integrate research findings from the McPeak-Sirois Consortium into clinical practice to improve patient outcomes.
<p>8h10 - 8h40</p>	<p>Decision-Making in Neoadjuvant Treatment for Surgeons Dr. Kerianne Boulva CHUM Learning Objectives:</p> <ul style="list-style-type: none">• Discuss indications for neoadjuvant treatment of breast cancer and preferred treatments based on cancer type.• Evaluate response to neoadjuvant treatment and its impact on surgical decisions.
<p>8h40 - 9h00</p>	<p>Personalization of Neoadjuvant and Adjuvant Treatment for HER2+ Disease Dr. Lucas Sideris University of Montreal Learning Objectives:</p> <ul style="list-style-type: none">• Describe indications for systemic treatment in early HER2+ breast cancer.• Review the available systemic treatment options in 2024.
<p>9h00 - 9h20</p>	<p>Early Triple-Negative Breast Cancer Management Dr. Kim Ma Jewish General Hospital Learning Objectives:</p> <ul style="list-style-type: none">• Describe current therapeutic approaches for early triple-negative breast cancer.• Evaluate the efficacy of neoadjuvant and adjuvant treatments in managing triple-negative breast cancer.• Integrate new therapeutic options, including immunotherapies and targeted therapies, to improve clinical outcomes for patients with early triple-negative breast cancer.

November 22

<p>9h20 - 9h40</p>	<p>Managing Side Effects of CDK 4/6 Inhibitors and Immunotherapy Dr. Sara Soldera MUHC Learning Objectives:</p> <ul style="list-style-type: none">• Identify common side effects associated with CDK 4/6 inhibitors and immunotherapy in cancer treatment.• Evaluate strategies to manage side effects and minimize their impact on patients' quality of life.• Apply adapted protocols to ensure treatment adherence while reducing complications associated with CDK 4/6 inhibitors and immunotherapy.
<p>9h40 - 9h55</p>	<p>Question Period Panel: Dr. Kerianne Boulva, Dr. Lucas Sideris, Dr. Kim Ma, Dr. Sara Soldera</p>
<p>9h55 - 10h15</p>	<p>Tumor Board Discussion Panel: Dr. Kerianne Boulva, Dr. Lucas Sideris, Dr. Kim Ma, Dr. Sara Soldera Learning Objectives:</p> <ul style="list-style-type: none">• Discuss indications for neoadjuvant treatment based on breast cancer type and analyze how treatment response influences surgical decisions.• Identify criteria for systemic treatments in early HER2+ breast cancer and review options for triple-negative breast cancer.• Assess the side effects of CDK 4/6 inhibitors and immunotherapy and implement effective management strategies to improve patient quality of life and treatment adherence.
<p>10h15 - 10h35</p>	<p>Break and Networking</p>
<p>10h35 - 11h00</p>	<p>HER2+ Metastatic Breast Cancer Dr. Danielle Charpentier CHUM Learning Objectives:</p> <ul style="list-style-type: none">• Describe treatment options for HER2+ metastatic breast cancer and integrate clinical trial findings into current practice.• Discuss optimal treatment sequences and algorithms for HER2+ metastatic breast cancer.• Optimize surveillance, prevention, and early recognition of adverse events and approaches for patients with brain metastases.

November 22

<p>11h00 - 11h25</p>	<p>HR+ Metastatic Breast Cancer Dr. Jamil Asselah MUHC Learning Objectives:</p> <ul style="list-style-type: none">• Describe current therapeutic options for HR+ metastatic breast cancer, including hormonal and targeted therapies.• Analyze factors influencing treatment choices in HR+ metastatic breast cancer, including resistance to hormonal therapies.• Incorporate new therapeutic approaches to improve survival and quality of life for patients with HR+ metastatic breast cancer.
<p>11h25 - 12h10</p>	<p>Early HR+ Breast Cancer: Benefits of Neoadjuvant/Adjuvant Treatment? Dr. Joyce O'Shaughnessy Texas Oncology Learning Objectives:</p> <ul style="list-style-type: none">• Describe indications and benefits of neoadjuvant/adjuvant treatment in early HR+ breast cancer.• Evaluate survival and recurrence reduction benefits associated with hormonal and systemic therapies in neoadjuvant/adjuvant settings.• Apply recent data to optimize therapeutic strategies for early HR+ breast cancer patients.
<p>12h10 - 12h25</p>	<p>Question Period Panel: Dr. Danielle Charpentier, Dr. Jamil Asselah, Dr. Joyce O'Shaughnessy</p>
<p>12h25 - 12h45</p>	<p>Tumor Board Discussion Panel: Dr. Danielle Charpentier, Dr. Jamil Asselah, Dr. Joyce O'Shaughnessy Learning Objectives:</p> <ul style="list-style-type: none">• Analyze current therapeutic options for HER2+ and HR+ metastatic breast cancer, incorporating new clinical trial findings to improve management and patient quality of life.• Evaluate optimal treatment sequences and algorithms for metastatic breast cancer, including resistance management and brain metastases.• Integrate the benefits of neoadjuvant/adjuvant treatment in early HR+ breast cancer based on recent data to optimize clinical outcomes and reduce recurrence.
<p>12h45- 13h45</p>	<p>Lunch and Networking</p>

November 22

<p>13h45 -14h50</p>	<p>Oncoplastic Surgery Facilitators: Dr. Ahmad Kaviani and Dr. Melissa Kyriakos Learning Objectives:</p> <ul style="list-style-type: none">• Explore oncoplastic surgery techniques to improve aesthetic and functional outcomes after breast-conserving surgery.• Discuss indications and patient selection criteria for oncoplastic approaches in breast cancer treatment.• Propose innovative strategies to integrate oncoplastic techniques into comprehensive breast cancer management, considering clinical challenges and patient preferences.
<p>13h45 -14h50</p>	<p>Advances in Breast Pathology and Biomarkers as Therapeutic Targets Facilitators: Dr. Danh Tran-Thanh and Dr. Jamil Asselah Learning Objectives:</p> <ul style="list-style-type: none">• Discuss recent advances in breast pathology, focusing on identifying and using biomarkers as therapeutic targets.• Evaluate the impact of biomarkers on personalized treatments and patient management in breast cancer.• Integrate new biomarkers into diagnostic and therapeutic strategies to optimize clinical outcomes.
<p>13h45 -14h50</p>	<p>Use of CDK 4/6 Inhibitors in Early Breast Cancer Facilitators: Dr. Erica Patocskai and Dr. Rami Younan Learning Objectives:</p> <ul style="list-style-type: none">• Examine recent clinical data on CDK 4/6 inhibitors in early breast cancer treatment.• Evaluate the benefits and risks of integrating CDK 4/6 inhibitors into adjuvant treatment protocols for HR+ breast cancer patients.• Discuss patient selection criteria and the potential impact on survival and recurrence in early breast cancer.
<p>13h45 -14h50</p>	<p>Mainstream Genetic Testing for Early Breast Cancer: How Do I Implement It? Facilitators: Dr. Dominique Boudreau and Dr. Maude Lefebvre Learning Objectives:</p> <ul style="list-style-type: none">• Describe indications and eligibility criteria for genetic testing in early breast cancer.• Evaluate the impact of genetic testing on therapeutic decisions and risk management for patients and their families.• Propose strategies to effectively integrate genetic testing into routine clinical practice, considering available resources and ethical implications.

November 22

14h50 - 15h20	Summary and Sharing from Small Group Sessions
15h20 - 16h05	<p>Germline and Somatic Testing in Early Breast Cancer in 2024 Dr. Joyce O'Shaughnessy Texas Oncology Learning Objectives:</p> <ul style="list-style-type: none">• Differentiate between germline and somatic testing in diagnosing and managing early breast cancer.• Evaluate the impact of germline and somatic genetic testing on therapeutic options and clinical decision-making in 2024.• Integrate current recommendations for using germline and somatic testing into personalized treatment for early breast cancer patients.
14h50 - 15h20	Question Period
16h20	Closing Remarks
16h20 - 17h20	Cocktail

